Journal
ARTHRITIS CARE & RESEARCH
Volume 66, Issue 11, Pages 1731-1739Publisher
WILEY
DOI: 10.1002/acr.22339
Keywords
-
Categories
Funding
- NIH/National Institute for Arthritis and Musculoskeletal and Skin Disease [UO1-AR-055057, K24-AR-063120-02]
- Rheumatology Research Foundation Medical Student Research Preceptorship
- Intermune
- EMD Serono
- Biogene Idec
- Roche
- DART Therapeutics and Sigma Tau
- Actelion
- Bayer
- BMS
- Digna
- Genentech/Roche
- Merck
- Sanofi-Aventis/Genzyme
Ask authors/readers for more resources
Objective. Skin and musculoskeletal involvement are frequently present early in diffuse cutaneous systemic sclerosis (dcSSc). The current study examined the correlates for skin and musculoskeletal measures in a 1-year longitudinal observational study. Methods. Patients with dcSSc were recruited at 4 US centers and enrolled in a 1-year study. Prespecified and standardized measures included physician and patient assessments of skin involvement, modified Rodnan skin score (MRSS), durometer score, Health Assessment Questionnaire disability index, serum creatine phosphokinase, tender joint counts, and presence/absence of tendon friction rubs, small joint contractures, and large joint contractures. Additionally, physician and patient global health assessments and health-related quality of life assessments were recorded. Correlations were computed among the baseline global assessments, skin variables, and musculoskeletal variables. Using the followup physician and patient anchors, effect sizes were calculated. Results. A total of 200 patients were studied: 75% were women, mean +/- SD age was 50.0 +/- 11.9 years, and mean +/- SD disease duration from first non-Raynaud's phenomenon symptom was 1.6 +/- 1.4 years. Physician global health assessment had large correlations with MRSS (r = 0.60) and physician-reported skin involvement visual analog scale in the last month (r = 0.74), whereas patient global assessment had large correlations with MRSS, the Short Form 36 health survey physical component scale, skin interference, and skin involvement in the last month (r = 0.37-.72). Four of 9 skin variables had moderate to large effect sizes (0.51-1.09). Conclusion. Physician and patient global assessments have larger correlations with skin measures compared to musculoskeletal measures. From a clinical trial perspective, skin variables were more responsive to change than musculoskeletal variables over a 1-year period, although both provide complementary information.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available